In this study, we established an HPLC-MS method to determine gypenoside XVⅡ in biosamples. The methodology results indicated that the linear range was 1-2 500 μg•L⁻¹ (r=0.996 3); intraday RSD values for high, medium and low concentrations were 9.9%, 3.0% 1.7%; interday RSD values were 16%, 14%, 2.5%; matrix effect ranged between 90.0%-100%, with RSD<15%. The recovery was more than 80.0%, with precision and accuracy in line with request. After the rats were orally and intravenously administered with gypenoside XVⅡ, the concentrations of gypenoside XVⅡ in plasma were determined, and pharmacokinetic parameter was calculated using pharmacokinetic software DAS 2.0. According to the main pharmacokinetic parameters of gypenoside XVⅡ, tmax was 0.17-0.20 h, t1/2 was 1.94-2.56 h, bioavailability of oral administration was 1.87%. The results indicated that the pharmacokinetic profiles of gypenoside XVⅡ were rapid absorption and distribution after oral administration, short time to peak and rapid elimination.
Keywords: LC-MS/MS; pharmacokinetics; plasma concentration; pypenoside XVⅡ.
Copyright© by the Chinese Pharmaceutical Association.